Suppr超能文献

Phase II trial of trimelamol in refractory ovarian cancer.

作者信息

Judson I R, Calvert A H, Gore M E, Balmanno K, Gumbrell L A, Perren T, Wiltshaw E

机构信息

Section of Drug Development, Institute of Cancer Research, Royal Marsden Hospital, UK.

出版信息

Br J Cancer. 1991 Feb;63(2):311-3. doi: 10.1038/bjc.1991.72.

DOI:10.1038/bjc.1991.72
PMID:1997112
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC1971798/
Abstract

Trimelamol is an analogue of hexamethymelamine which exhibited activity against refractory ovarian cancer in phase I clinical trial. The dose limiting toxicity was leukopenia. In a phase II study, 42 patients with recurrent, or platinum-complex resistant, advanced ovarian cancer were treated using the dose schedule 800 mg m-2 i.v. daily for 3 days. There were one complete, three partial and five minor responses, objective response rate: 9.5%. The main toxicity observed was nausea and vomiting, myelosuppression was minor. The role of Trimelamol in the treatment of ovarian cancer remains to be defined, but its activity is limited in refractory disease.

摘要

相似文献

1
Phase II trial of trimelamol in refractory ovarian cancer.
Br J Cancer. 1991 Feb;63(2):311-3. doi: 10.1038/bjc.1991.72.
2
Phase I trial and pharmacokinetics of trimelamol (N2,N4,N6-trihydroxymethyl-N2,N4,N6-trimethylmelamine).曲美仑莫（N2,N4,N6-三羟甲基-N2,N4,N6-三甲基三聚氰胺）的I期试验及药代动力学
Cancer Res. 1989 Oct 1;49(19):5475-9.
3
Efficacy and safety of topotecan in the treatment of advanced ovarian carcinoma.拓扑替康治疗晚期卵巢癌的疗效与安全性。
Semin Oncol. 1997 Feb;24(1 Suppl 5):S5-19-S5-25.
4
Superior efficacy of trimelamol to hexamethylmelamine in human ovarian cancer xenografts.
Cancer Chemother Pharmacol. 1986;18(2):124-8. doi: 10.1007/BF00262280.
5
Modulation of platinum sensitivity and resistance by cyclosporin A in refractory ovarian and fallopian tube cancer patients: a phase II study.环孢素A对难治性卵巢癌和输卵管癌患者铂敏感性及耐药性的调节作用：一项II期研究
Clin Cancer Res. 1996 Oct;2(10):1693-7.
6
Hexamethylmelamine (NSC-13875) in the treatment of advanced cancer.
Cancer Chemother Rep. 1972 Aug;56(4):505-14.
7
A phase II trial of gallium nitrate (NSC #15200) in previously treated ovarian carcinoma. A Gynecologic Oncology Group Study.
Am J Clin Oncol. 1991 Aug;14(4):349-51. doi: 10.1097/00000421-199108000-00015.
8
Phase I trial of intravenous carboplatin and cyclosporin A in refractory gynecologic cancer patients.静脉注射卡铂和环孢素A用于难治性妇科癌症患者的I期试验。
Clin Cancer Res. 1996 Oct;2(10):1699-704.
9
Phase II study of Baker's antifol (triazinate, TZT, NSC 139, 105) in advanced carcinoma of the ovary. A Gynecologic Oncology Group study.贝克抗叶酸剂（三嗪酸，TZT，NSC 139,105）用于晚期卵巢癌的II期研究。一项妇科肿瘤学组研究。
Invest New Drugs. 1983;1(2):185-8. doi: 10.1007/BF00172079.
10
Phase 2 evaluation of topotecan administered on a 3-day schedule in the treatment of platinum- and paclitaxel-refractory ovarian cancer.拓扑替康按3天给药方案治疗铂类和紫杉醇难治性卵巢癌的2期评估。
Gynecol Oncol. 2000 Oct;79(1):116-9. doi: 10.1006/gyno.2000.5902.

引用本文的文献

1
CRC/EORTC/NCI Joint Formulation Working Party: experiences in the formulation of investigational cytotoxic drugs.结直肠癌/欧洲癌症研究与治疗组织/美国国立癌症研究所联合制定工作组：细胞毒性研究用药物制定经验
Br J Cancer. 1995 Jul;72(1):210-8. doi: 10.1038/bjc.1995.305.

本文引用的文献

1
The comparative pharmacokinetics of pentamethylmelamine in man, rat, and mouse.五甲基三聚氰胺在人、大鼠和小鼠体内的比较药代动力学。
Cancer Chemother Pharmacol. 1982;8(1):105-11. doi: 10.1007/BF00292880.
2
In vitro cytotoxicity of the methylmelamines.甲基三聚氰胺的体外细胞毒性。
Chem Biol Interact. 1980 Feb;29(2):235-46. doi: 10.1016/0009-2797(80)90036-8.
3
Low central nervous system penetration of N2,N4,N6,-trihydroxymethyl-N2,N4,N6,-trimethylmelamine (Trimelamol): a cytotoxic s-triazine with reduced neurotoxicity.N2,N4,N6-三羟甲基-N2,N4,N6-三甲基三聚氰胺（曲美莫林）的中枢神经系统低渗透性：一种具有降低神经毒性的细胞毒性均三嗪。
Br J Cancer. 1986 May;53(5):601-6. doi: 10.1038/bjc.1986.102.
4
Prevention of emesis in patients receiving cytotoxic drugs by GR38032F, a selective 5-HT3 receptor antagonist.
Lancet. 1987 Jun 27;1(8548):1461-3. doi: 10.1016/s0140-6736(87)92208-2.
5
The anti-emetic potential of the 5-hydroxytryptamine3 receptor antagonist BRL 43694.5-羟色胺3受体拮抗剂BRL 43694的止吐潜力
Br J Cancer. 1988 Nov;58(5):644-50. doi: 10.1038/bjc.1988.277.
6
Response of patients in phase II studies of chemotherapy in ovarian cancer: implications for patient treatment and the design of phase II trials.卵巢癌化疗II期研究中患者的反应：对患者治疗及II期试验设计的启示
Br J Cancer. 1989 Apr;59(4):650-3. doi: 10.1038/bjc.1989.132.
7
Phase I trial and pharmacokinetics of trimelamol (N2,N4,N6-trihydroxymethyl-N2,N4,N6-trimethylmelamine).曲美仑莫（N2,N4,N6-三羟甲基-N2,N4,N6-三甲基三聚氰胺）的I期试验及药代动力学
Cancer Res. 1989 Oct 1;49(19):5475-9.
8
Treatment of relapsed carcinoma of the ovary with cisplatin or carboplatin following initial treatment with these compounds.
Gynecol Oncol. 1990 Feb;36(2):207-11. doi: 10.1016/0090-8258(90)90174-j.
9
In vitro studies with hexamethylmelamine.六甲基三聚氰胺的体外研究。
Biochem Pharmacol. 1977 Dec 15;26(24):2385-91. doi: 10.1016/0006-2952(77)90446-4.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验